Augurex Life Sciences, Quest Diagnostics collaborate to improve rheumatoid arthritis diagnosis and management: Vancouver, Canada Monday, November 18, 2024, 16:00 Hrs [IST] Augurex ...
The test will measure levels of the 14-3-3eta protein, which is used in the diagnosis and management of inflammatory diseases including rheumatoid arthritis.
Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury ...
Inc. (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's ...
at 07:05 Augurex and New Day Diagnostics Announce Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents; Enabling a First-In-Class Diagnostic Test for Axial Spondyloarthritis Augurex Life ...
Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced its participation at the American College of Rheumatology (ACR) Convergence 2024, taking place in ...
NEW YORK – The US Department of Justice said this week that a California-based mobile phlebotomy company and its owners have agreed to pay at least $135,000 to resolve fraud charges. According to ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that ARUP Laboratories, a leading national reference ...
A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...
TEHRAN, Iran (AP) — An Iranian newspaper implying that the public needed to have the patience of the Biblical figure Job in waiting for President Masoud Pezeshkian to lift restrictions on the internet ...
Last month, Donald Trump announced that he was selling limited-edition, gaudy watches ranging from $499 to the bargain price of $100,000, bragging about their Swiss-made precision. But a CNN ...